Grünenthal Press Releases 2015

Aachen, 19th November 2015. Steffen Fritzsche (51) has been Head of Corporate Communications at Grünenthal since 1st November 2015. In this position he supports the Corporate Executive Board in internal and external communications regarding all matters of corporate interest. He succeeds Friederike Herrfurth, who left the company at her own request.

• After the acquisition of Nucynta® (tapentadol) and Nucynta® ER (tapentadol extended release tables) for the U.S. territory by Depomed earlier this year, this is the second pain drug from Grünenthal’s Research and Development that will be added to Depomed’s portfolio of innovative medicines in pain and neurology
• Grünenthal and Depomed, Inc., applied a creative deal structure for this exclusive license agreement on Cebranopadol

• New approach to networked research and development brings research experts, companies and laboratories together to develop new treatment option for patients with fibrosis
• In fibrosis patients, an overproduction of connective tissue can ultimately lead to organ failure

• Regulatory Authority of Brazil, ANVISA, certifies Tecnandina with zero findings
• Tecnandina to be first production plant in Ecuador to be ANVISA certified
• Tecnandina to start manufacturing for international clients in Brazil and Mexico

• Grünenthal receives EU Marketing Authorization for Zalviso^® 15 micrograms sublingual tablets for treatment of acute moderate to severe post-operative pain in adult patients
• Zalviso^® represents first step for Grünenthal to enter into hospital market, building on its leadership in pain therapy innovation

• Novel ideas for potential improvement of pain management
• High need for translation of findings into practice for improved patients’ quality of life

• Positive CHMP opinion marks a key milestone towards availability in the EU
• Once approved, Zalviso^® represents a new system for patients to self-administer sublingual sufentanil after surgery

• Partnership program with Proteus S.A. (Chile) and Boston Children’s Hospital (USA)
• Grünenthal’s Innovative Medicines Unit driving the program in a new approach to research & development
  

Brussels/Aachen, June 12th, 2015. Pain is a common condition, which affects one in five adult citizens in Europe. They have persistent or chronic pain, a condition which affects the everyday lives of millions of people worldwide and which also poses a huge economic burden. Since 2004 the European Pain Federation EFIC® has cooperated with the pharmaceutical company Grünenthal GmbH, to support up-and-coming pain scientists in translating their experimental project ideas into funded pain research projects. The focus lies on novel ideas with potential for achieving major advances in the understanding of pain mechanisms and its treatment.

• Member of the European Parliament (MEP) Interest Group aims at raising awareness of neurological and chronic pain disorders and encouraging research and access to innovative treatments
• Grünenthal co-sponsors the initiative and presents the interactive ‘pain box’ experience at the European launch event